CMPI insider filings

Checkmate Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-05-31. Screen CMPI transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CMPI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Checkmate Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2022-05-314Isacoff Oren — DirectorDisposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2022-05-314Colabuono Peter — DirectorDisposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2022-05-314Yan Joy — DirectorDisposition to issuer (D): 20,061 (derivative)EDGAR
2022-05-314Dolski Robert — Chief Financial OfficerDisposition to issuer (D): 101,180 (derivative) · Disposition to issuer (D): 27,300 (derivative) · Disposition to issuer (D): 150,000 (derivative)EDGAR
2022-05-314Wooldridge James — Chief Medical OfficerDisposition to issuer (D): 54,600 (derivative) · Disposition to issuer (D): 101,180 (derivative) · Disposition to issuer (D): 27,300 (derivative) · Disposition to issuer (D): 150,818 (derivative) · Disposition to issuer (D): 95,916 (derivative)EDGAR
2022-05-314BASH ALAN — Chief Executive Officer, DirectorDisposition to issuer (D): 575,000 (derivative)EDGAR
2022-05-314Wigginton Jon Marc — DirectorDisposition to issuer (D): 20,061 (derivative)EDGAR
2022-05-314Flaherty Keith T. — DirectorDisposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 4,012 (derivative) · Disposition to issuer (D): 22,736 (derivative)EDGAR
2022-05-314Fuhrman Alan — DirectorDisposition to issuer (D): 246,671 (derivative) · Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 22,736 (derivative)EDGAR
2022-05-314POWELL MICHAEL — DirectorDisposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 30,000 (derivative)EDGAR
2022-05-174venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 35,850 @ $10.45 · Sale (S): 95,800 @ $10.45EDGAR
2022-05-124venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 18,676 @ $10.38 · Sale (S): 17,700 @ $10.38 · Sale (S): 124,525 @ $10.39EDGAR
2022-05-094venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 20,743 @ $10.37 · Sale (S): 48,334 @ $10.37 · Sale (S): 17,600 @ $10.37EDGAR
2022-05-044venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 153,700 @ $10.38 · Sale (S): 79,475 @ $10.37 · Sale (S): 37,500 @ $10.37EDGAR
2022-04-294venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 47,396 @ $10.38 · Sale (S): 73,400 @ $10.38 · Sale (S): 69,230 @ $10.38EDGAR
2022-04-284Wooldridge James — Chief Medical OfficerGrant/award (A): 54,600 (derivative) @ $0EDGAR
2022-04-264venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 37,430 @ $10.39 · Sale (S): 27,668 @ $10.39 · Sale (S): 64,683 @ $10.38EDGAR
2022-04-214venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Sale (S): 399,923 @ $10.42 · Sale (S): 85,611 @ $10.39 · Sale (S): 62,200 @ $10.38EDGAR
2022-03-024BASH ALAN — Chief Executive Officer, DirectorGrant/award (A): 575,000 (derivative) @ $0EDGAR
2022-02-254Novo Holdings A/S — 10% ownerSale (S): 1,820 @ $2.90 · Sale (S): 5,990 @ $2.83 · Sale (S): 300 @ $2.70EDGAR
2022-02-014Wigginton Jon Marc — DirectorGrant/award (A): 20,061 (derivative) @ $0EDGAR
2022-01-314Dolski Robert — Chief Financial OfficerGrant/award (A): 101,180 (derivative) @ $0EDGAR
2022-01-314Wooldridge James — Chief Medical OfficerGrant/award (A): 101,180 (derivative) @ $0EDGAR
2021-12-174Yan Joy — DirectorGrant/award (A): 20,061 (derivative) @ $0EDGAR
2021-10-294Fuhrman Alan — See Remarks, DirectorGrant/award (A): 246,671 (derivative) @ $0EDGAR
2021-08-104POWELL MICHAEL — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2021-08-064Dolski Robert — Chief Financial OfficerGrant/award (A): 27,300 (derivative) @ $0EDGAR
2021-08-064Wooldridge James — Chief Medical OfficerGrant/award (A): 27,300 (derivative) @ $0EDGAR
2021-08-064Chaudhary Kleem — Chief Business OfficerGrant/award (A): 27,300 (derivative) @ $0EDGAR
2021-08-064Labinger Barry — President and CEO, DirectorGrant/award (A): 85,950 (derivative) @ $0EDGAR
2021-06-214Isacoff Oren — DirectorGrant/award (A): 10,030 (derivative) @ $0EDGAR
2021-06-214Colabuono Peter — DirectorGrant/award (A): 10,030 (derivative) @ $0EDGAR
2021-06-214Flaherty Keith T. — DirectorGrant/award (A): 10,030 (derivative) @ $0EDGAR
2021-06-214Krieg Arthur M — Chief Scientific OfficerPurchase (P): 7,224 @ $6.04EDGAR
2021-06-214Fuhrman Alan — DirectorGrant/award (A): 10,030 (derivative) @ $0EDGAR
2021-06-214POWELL MICHAEL — DirectorGrant/award (A): 10,030 (derivative) @ $0EDGAR
2021-06-174Krieg Arthur M — Chief Scientific OfficerPurchase (P): 3,578 @ $6.18EDGAR
2021-06-014Krieg Arthur M — Chief Scientific OfficerOther (J): 68,457 @ $0 · Other (J): 68,457 @ $0 · Other (J): 68,457 @ $0EDGAR
2021-05-194Krieg Arthur M — Chief Scientific OfficerPurchase (P): 25,001 @ $6.97EDGAR
2021-03-314Krieg Arthur M — Chief Scientific OfficerPurchase (P): 17,468 @ $10.94 · Purchase (P): 15,752 @ $11.40EDGAR
2021-03-294Krieg Arthur M — Chief Scientific OfficerPurchase (P): 10,036 @ $12.35 · Purchase (P): 3,484 @ $12.15EDGAR
2021-03-014Chaudhary Kleem — Chief Business OfficerOption exercise (M): 2,000 @ $2.62 · Option exercise (M): 2,000 (derivative) @ $0EDGAR
2021-01-284Krieg Arthur M — Chief Scientific OfficerPurchase (P): 1,701 @ $13.05EDGAR
2021-01-214Krieg Arthur M — Chief Scientific OfficerPurchase (P): 500 @ $13.09EDGAR
2021-01-154Chaudhary Kleem — Chief Business OfficerOption exercise (M): 2,000 @ $2.62 · Option exercise (M): 2,000 (derivative) @ $0EDGAR
2020-12-314Krieg Arthur M — Chief Scientific OfficerPurchase (P): 443 @ $14.16EDGAR
2020-12-234Chaudhary Kleem — Chief Business OfficerOption exercise (M): 4,000 @ $2.62 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2020-12-234Krieg Arthur M — Chief Scientific OfficerPurchase (P): 5,103 @ $14.64EDGAR
2020-12-174Krieg Arthur M — Chief Scientific OfficerPurchase (P): 42 @ $14.49 · Purchase (P): 4,805 @ $14.62EDGAR
2020-11-124POWELL MICHAEL — Director, 10% ownerGrant/award (A): 30,000 (derivative) @ $0EDGAR

Recent 8-K events — Checkmate Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2022-05-318-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2022-05-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-04-198-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-04-198-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2022-03-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-03-018-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2022-02-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2022-02-018-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2021-12-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2021-12-148-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CMPI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs